Journal of cardiology最新文献

{"title":"Pathophysiology and management of adults with complex congenital heart disease after biventricular repair.","authors":"Mitsutaka Nakashima, Norihisa Toh, Takashi Miki, Yoichi Takaya, Koji Nakagawa, Kazuhiro Omori, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Morita, Teiji Akagi, Shinsuke Yuasa","doi":"10.1016/j.jjcc.2025.03.014","DOIUrl":"10.1016/j.jjcc.2025.03.014","url":null,"abstract":"<p><p>Surgical management of congenital heart disease encompasses a spectrum of procedures, ranging from biventricular repair to univentricular palliation, each tailored to the specific anatomical and hemodynamic features of individual cases. Among these, biventricular repair, which preserves a functional ventricle to sustain pulmonary circulation, is prioritized whenever feasible. Advances in approaches have significantly improved outcomes, enabling many patients with congenital heart disease to reach adulthood, including the majority who have undergone biventricular repair. Despite these advancements, long-term complications-such as valvular disease, arrhythmias, heart failure, outflow tract obstruction, and dysfunction of extracardiac conduits-pose persistent challenges in the lifelong care of these patients. This review examines the distinct challenges and management strategies associated with adult patients who have undergone biventricular repair for complex congenital heart disease. The discussion focuses on key conditions, including repaired tetralogy of Fallot, transposition of the great arteries following atrial or arterial switch procedures, surgically managed or untreated congenitally corrected transposition of the great arteries with significant tricuspid regurgitation necessitating intervention, pulmonary atresia with intact ventricular septum, and Ebstein's anomaly. By addressing the long-term complications and therapeutic considerations unique to this patient population, this review aims to provide a comprehensive framework for optimizing care as these individuals transition into adulthood.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twelve-year trends of hospitalizations and survival of acute decompensated heart failure: Data from a regional tertiary center.","authors":"Keiichi Tsuchida, Naohito Tanabe, Komei Tanaka, Kazue Ozeki, Akihiko Miyasaka, Tatsuya Inazuki, Mio Abe, Hikaru Katagiri, Ryuji Kobayashi, Yuko Kurashima, Norihito Oyanagi, Shintaro Yoneyama, Asami Kashiwa, Yuka Hayashi, Yukio Hosaka, Kazuyuki Ozaki, Kazuyoshi Takahashi","doi":"10.1016/j.jjcc.2025.03.012","DOIUrl":"10.1016/j.jjcc.2025.03.012","url":null,"abstract":"<p><strong>Background: </strong>Recent trends in in-hospital acute decompensated heart failure (ADHF) have been reported in several registry studies demonstrating no improvement in terms of mortality rate and readmission rate due to heart failure (HF) exacerbation. Trends in management of ADHF may be different in areas where the aging rate is faster.</p><p><strong>Methods: </strong>We retrospectively enrolled 1121 ADHF patients hospitalized between 2008 and 2019. The study patients were classified into three groups based on 4-year periods. Our primary study interests were trends over time in age, length of hospital stay, and clinical outcomes, with endpoints, including 1-year mortality and readmission for HF (reHF).</p><p><strong>Results: </strong>During the 12-year period, the length of hospital stay was not reduced, but rather prolonged in Period 3 (p < 0.001). Temporal trends in 1-year clinical outcomes showed both 1-year all-cause and cardiovascular mortality tended to increase. No improvement in 1-year reHF rates was observed over time. All-cause mortality was associated with Period 2 (95%CI 1.02-4.97), Period 3 (95%CI 1.30-6.05), older age (≥79 years, 95%CI 1.01-3.20), decreased left ventricular ejection fraction (95%CI 1.08-3.62), higher loop diuretics dose (95%CI 1.07-1.25), higher B-type natriuretic peptide (BNP) levels (95%CI 1.00, 1.01), and decreased hemoglobin levels (95%CI 0.74-0.97). Factors associated with cardiovascular mortality included Period 3 (95%CI 1.02-7.31), higher loop diuretics dose (HR 1.17, 95%CI 1.07-1.27), higher BNP levels (95%CI1.00-1.01), and lower estimated glomerular filtration rate (eGFR) levels on admission (95%CI 0.70-0.95). Predictors of reHF were number of previous HF hospitalizations (95%CI 1.13-1.94), lower eGFR levels (95%CI 0.79-0.94) on admission and suboptimal guideline-directed medical therapy (95%CI 0.50-0.79).</p><p><strong>Conclusions: </strong>Despite the recent advances in medical therapy, readmission rate in patients with ADHF did not improve during the 12-year observation period. The mortality rate worsened over time. These findings warrant prompt establishment of more effective approaches to prevent and treat ADHF.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on preventing atrial arrhythmia recurrences after atrial fibrillation ablation in patients with heart failure.","authors":"Takashi Okajima, Shinji Ishikawa, Yusuke Uemura, Yuta Ozaki, Shogo Yamaguchi, Takayuki Mitsuda, Kenji Takemoto, Yasuya Inden, Toyoaki Murohara, Masato Watarai","doi":"10.1016/j.jjcc.2025.03.013","DOIUrl":"10.1016/j.jjcc.2025.03.013","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is frequently observed in patients with heart failure (HF), and the efficacy of catheter ablation for AF treatment has been established; however, recurrence of atrial arrhythmia is possible. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been reported to suppress AF recurrence in patients with diabetes; however, the efficacy of SGLT2i after AF ablation in patients with HF has not been fully elucidated.</p><p><strong>Methods: </strong>A total of 141 consecutive patients with HF aged ≤75 years who underwent AF ablation were analyzed. Patients with follow-up shorter than six months were excluded. The primary endpoint was atrial arrhythmia recurrence after a 3-month blanking period. The type of recurrence, incidence of hospitalization for HF, and mortality rates were also evaluated.</p><p><strong>Results: </strong>Forty-five patients used SGLT2i, and the median follow-up period was 372 days. The incidence of atrial arrhythmia recurrence was significantly lower in patients taking SGLT2i than in those that were not taking SGLT2i (20.0 % vs. 38.5 %, p = 0.029; log-rank test, p = 0.034). In the multivariate analysis, intake of SGLT2i was associated with a low risk of atrial arrhythmia recurrence (hazard ratio: 0.38, 95 % confidence interval: 0.18-0.80, p = 0.010). The rate of AF recurrence was significantly lower than the rate of atrial tachycardia/flutter recurrence in the SGLT2i group (44.4 % vs. 83.8 %; p = 0.013). The incidence of hospitalization for HF and/or death was low in both groups (0 % in the SGLT2i group and 1.0 % in the non-SGLT2i group). In 24 propensity score-matched pairs, the SGLT2i group had a lower recurrence rate (16.7 % vs. 45.8 %, p = 0.029, log-rank test, p = 0.047) than the non-SGLT2i group.</p><p><strong>Conclusions: </strong>SGLT2i use in patients with HF was associated with a lower atrial arrhythmia recurrence after AF ablation; hence, SGLT2i administration for patients with HF who will undergo AF ablation may be beneficial.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of leadless cardiac resynchronization therapy: An updated meta-analysis.","authors":"Konstantinos Kolokathis, Ioannis Doundoulakis, Dimitrios Tsiachris, Athanasios Kordalis, Konstantinos Tsioufis","doi":"10.1016/j.jjcc.2025.03.010","DOIUrl":"10.1016/j.jjcc.2025.03.010","url":null,"abstract":"<p><strong>Background: </strong>The WiSE cardiac resynchronization therapy (CRT) system (EBR Systems Inc., Sunnyvale, CA, USA) is an innovative technique consisting of an electrode implanted in the endocardium of the left ventricle as an alternative to the conventional CRT for symptomatic patients with heart failure and reduced ejection fraction (EF) despite optimal medical treatment. The objective of this study was to evaluate the efficacy of the Wise CRT.</p><p><strong>Methods: </strong>We searched two electronic databases from inception until November 2024.The primary outcomes were defined as the mean difference (MD) of left ventricular (LV) EF (%) and QRS (milliseconds) from baseline to 6 months post-procedure.</p><p><strong>Results: </strong>Our analysis included six studies (n = 281 patients). A meta-analysis was performed with the primary endpoints being the MD between baseline LVEF and 6-month follow-up and b) the MD between baseline QRS and 6-month follow-up. There was a mean increase in LVEF of 5.78 % (MD 5.78 %; CI 4.37-7.19; p < 0.01) and a mean reduction in QRS duration of 37.08 ms (MD -37.08 ms; CI -45.72 to -28.44; p < 0.01).</p><p><strong>Conclusion: </strong>The WiSE CRT showed impressive electrocardiographic and echocardiographic responses in high-risk patients for whom conventional CRT implantation was impossible or resulted in suboptimal treatment.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating feasibility, health impact, and participant feedback of the Utah South Asian Cardiovascular Health Initiative (U-SACHI): A community-based screening and intervention program.","authors":"Kevin S Shah, Hafsa Zahid, Nagesh Gullapalli, Harini Krishnan, Korak Chakraborti, Elizabeth Dranow, Amy B Locke, Sarath Satheesan, Krishna M Sundar","doi":"10.1016/j.jjcc.2025.03.011","DOIUrl":"10.1016/j.jjcc.2025.03.011","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) is the leading cause of death globally. In the United States, South Asians have a higher prevalence and earlier onset of atherosclerotic cardiovascular disease (ASCVD) compared to other ethnic groups. This study assessed the feasibility, health impact, and feedback of a community-based screening and intervention program focused on South Asians in Utah.</p><p><strong>Methods: </strong>We conducted a feasibility study of the Utah South Asian Cardiovascular Health Initiative (U-SACHI) using the University of Utah Wellness Bus to perform cardiovascular screenings at the India Cultural Center (ICC) in Utah. Participants were South Asian adults aged 30+ without known severe cardiovascular disease. The screening included measurements of waist circumference, LDL, HDL, hemoglobin A1c, and lipoprotein(A). A monthly intervention program was offered to those who had at least one increased risk marker on a monthly basis. Metrics were measured before and after the intervention, and qualitative input was obtained.</p><p><strong>Results: </strong>The combined screening events participant cohort consisted of 179 adults of South Asian descent. Based on desirable levels for South Asians as set out by the National Lipid Association, elevated waist circumference, BMI, LDL, and total cholesterol were confirmed in this cohort. At least one increased risk marker was present in 70 % of the subjects. The intervention program involved forty participants, of whom twenty-one finished most sessions. After completion, participants showed small improvements in some risk measures. Qualitative feedback highlighted that individuals reported more physical activity, made healthier food choices, and had higher levels of awareness.</p><p><strong>Conclusion: </strong>The U-SACHI program is a feasible and effective model for improving cardiovascular health in South Asians through community-based screenings and culturally tailored interventions. This approach enhances early detection of CVD risk factors and also encourages sustainable lifestyle changes. Further research is necessary to explore strategies for improving long-term outcomes.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Milestones in therapeutic and antithrombotic strategies for chronic thromboembolic pulmonary hypertension.","authors":"Kazuya Hosokawa, Kohtaro Abe","doi":"10.1016/j.jjcc.2025.03.006","DOIUrl":"10.1016/j.jjcc.2025.03.006","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition caused by persistent thrombus obstructing the pulmonary arteries, resulting in pulmonary hypertension. Pulmonary endarterectomy remains the gold standard treatment and can provide dramatic improvement in eligible patients. However, approximately 40 % of patients are inoperable. Over the past years, several randomized controlled trials have explored pulmonary vasodilators and balloon pulmonary angioplasty. Based on these trials, a multimodal treatment approach has been established. Balloon pulmonary angioplasty has shown hemodynamic improvement rather than pulmonary vasodilators in randomized controlled trials. Similarly, lifelong anticoagulation therapy is the cornerstone of CTEPH management. While vitamin K antagonists such as warfarin have been the standard recommended by CTEPH guidelines, recent studies, including the CTEPH AC Registry and the KABUKI trial, suggest that direct oral anticoagulants may be safe and effective alternatives. Several ongoing randomized controlled trials aim to refine treatment strategies. The IMPACT-CTEPH trial is investigating whether the initial combination therapy (riociguat + macitentan) is superior to monotherapy before balloon pulmonary angioplasty. The GO-CTEPH trial compares the efficacy of pulmonary endarterectomy and balloon pulmonary angioplasty in eligible patients. The THERAPY-HYBRID-BPA trial is evaluating the need for continued riociguat after balloon pulmonary angioplasty. The FIND-DCR study is evaluating a new imaging modality for the early detection of CTEPH. As research advances, multimodal approaches combining surgical, interventional, and pharmacological treatments are expected to improve patient outcomes and shape the future of CTEPH management.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tricuspid regurgitation: Innovation, current landscape, and future perspective of transcatheter tricuspid valve interventions.","authors":"Atsushi Sugiura, Tetsu Tanaka, Refik Kavsur, Can Öztürk, Johanna Vogelhuber, Miriam Silaschi, Marcel Weber, Sebastian Zimmer, Georg Nickenig","doi":"10.1016/j.jjcc.2025.03.009","DOIUrl":"10.1016/j.jjcc.2025.03.009","url":null,"abstract":"<p><p>Tricuspid regurgitation (TR) is a prevalent cardiovascular disease necessitating innovative treatments. Assessing comorbidities, such as right ventricular dysfunction, is pivotal for the therapeutic strategy. Preprocedural echocardiographic assessments are crucial for achieving optimal TR reduction. Transcatheter interventions have emerged as less invasive therapies. Tricuspid transcatheter edge-to-edge repair is the predominant technology, proven safe and effective in reducing TR. Additionally, transcatheter tricuspid valve replacement and direct annuloplasty technologies have been developed and recognized as attractive alternatives, each with unique advantages. This review discusses the innovation, current landscape, and future perspective of transcatheter tricuspid valve interventions for treating TR.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of self-expanding TAVR in Japanese dialysis patients with severe aortic stenosis: 1-year outcomes.","authors":"Koki Shishido, Futoshi Yamanaka, Noriaki Moriyama, Tomoki Ochiai, Hirokazu Miyashita, Tsuyoshi Yamabe, Kenichiro Noguchi, Tohru Asai, Shuzo Kobayashi, Yu Jung Yeh, Shigeru Saito","doi":"10.1016/j.jjcc.2025.03.008","DOIUrl":"10.1016/j.jjcc.2025.03.008","url":null,"abstract":"<p><strong>Background: </strong>In Japan, transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEV) was approved for patients with severe aortic stenosis (AS) and on chronic maintenance dialysis in May 2023. This study assessed the safety and efficacy of TAVR with SEVs in this patient population.</p><p><strong>Methods: </strong>This prospective, non-randomized, single-center study evaluated the safety and effectiveness of TAVR using a supra-annular SEV in Japanese patients with severe AS on chronic maintenance dialysis. The primary endpoint of all-cause mortality or disabling stroke and several secondary endpoints were assessed at 12 months.</p><p><strong>Results: </strong>Ten patients underwent TAVR using the Evolut platform (Medtronic, Minneapolis, MN, USA) between June 2020 and August 2022. Mean patient age was 80.0 ± 5.5 years and 70 % were male. Mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 7.4 ± 2.2 %. At 1 year, the primary endpoint occurred in two patients (20 %), and there were no strokes, aortic valve reinterventions, or new permanent pacemaker implantations. Valve hemodynamics improved postprocedure and were maintained in all patients reaching 12-month follow-up (mean effective orifice area 2.1 ± 0.4 cm², mean gradient 6.8 ± 1.6 mmHg), and no patients had moderate or severe aortic regurgitation.</p><p><strong>Conclusions: </strong>Japanese dialysis patients with severe AS who underwent TAVR using SEVs experienced favorable clinical and hemodynamic outcomes at 1-year follow-up. Further investigations are needed to assess long-term outcomes in this patient population.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in management strategies and clinical outcomes of venous thromboembolism in Japan from 2017 to 2023.","authors":"Wei Xiong, Yugo Yamashita, Toshiki Fukasawa, Chikashi Takeda, Hiroki Shiomi, Takahiro Horie, Koh Ono","doi":"10.1016/j.jjcc.2025.03.007","DOIUrl":"10.1016/j.jjcc.2025.03.007","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a major health problem worldwide. There are scarce data on the recent temporal trends of patients with VTE after the widespread use of direct oral anticoagulants (DOACs).</p><p><strong>Methods and results: </strong>In a Japanese nationwide hospital administrative database, we identified 20,217 patients with VTE from 2017 to 2023, and evaluated their temporal trends in management strategies and clinical outcomes. The proportions of outpatient treatment among patients with out-of-hospital isolated deep vein thrombosis increased significantly (p trend <0.001, Pearson's R = 0.046) over time from 2017 to 2023. The proportions of warfarin use decreased significantly over time from 2017 to 2023 (p trend <0.001, Pearson's R = -0.053), whereas the use of most DOACs increased. The proportions of thrombolysis (p trend <0.001, Pearson's R = -0.046) and inferior vena cave filter (p trend <0.001, Pearson's R = -0.048) use decreased significantly over time from 2017 to 2023. The incidence of 6-month all-cause death, VTE recurrence, and bleeding was 9.1 %, 2.1 %, and 4.4 %, respectively. The incidence decreased in 6-month all-cause death (p trend = 0.018, Pearson's R = -0.017) and bleeding (p trend <0.001, Pearson's R = -0.029) over time from 2017 to 2023.</p><p><strong>Conclusions: </strong>The current Japanese nationwide hospital administrative database provided the recent temporal trends in the real-world management strategies and clinical outcomes of VTE, which revealed several temporal changes in these aspects after the widespread use of DOACs.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future perspective regarding the clinical impact of very severe aortic stenosis following trans-catheter aortic valve implantation.","authors":"Hiroshi Onoda, Teruhiko Imamura","doi":"10.1016/j.jjcc.2025.03.003","DOIUrl":"10.1016/j.jjcc.2025.03.003","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}